Welcome to our dedicated page for CRA International news (Ticker: $CRAI), a resource for investors and traders seeking the latest updates and insights on CRA International stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRA International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRA International's position in the market.
Charles River Associates (CRA) reported record-breaking financial results for the first quarter of 2024, with revenue increasing by 12.4% to $171.8 million. The company achieved new quarterly records for net income, earnings per diluted share, and EBITDA. Eight out of eleven practices experienced growth, driving the strong financial performance. CRA also returned $12.3 million to shareholders through dividends and share repurchases. The company reaffirmed its financial guidance for full-year fiscal 2024, expecting revenue in the range of $645 million to $675 million.
Charles River Associates (CRA) has declared a quarterly cash dividend of $0.42 per common share. The dividend will be paid on June 14, 2024, to shareholders of record as of May 28, 2024. The company plans to continue paying quarterly dividends, subject to the discretion of the Board of Directors.
Charles River Associates (CRA) has strengthened its Antitrust & Competition Economics Practice by welcoming Dr. Svend Albæk, a former deputy chief economist of the European Commission's Directorate-General for Competition, as a senior consultant. With over 25 years of experience in European competition policy development, Dr. Albæk's addition enhances CRA's team, providing clients with expert economic analysis and regulatory advice worldwide.
